Sanders Robert P, Kocak Mehmet, Burger Peter C, Merchant Thomas E, Gajjar Amar, Broniscer Alberto
Division of Neuro-Oncology, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Pediatr Blood Cancer. 2007 Dec;49(7):888-93. doi: 10.1002/pbc.21272.
High-grade astrocytomas are rare in young children, but have been reported to have a better prognosis than similar tumors in older patients.
We retrospectively reviewed the clinical characteristics, survival, and long-term sequelae for patients younger than 3 years old with high-grade astrocytoma, treated at a single institution between 1984 and 2005.
Sixteen patients were included. Histology included anaplastic astrocytoma (n = 9), glioblastoma multiforme (n = 5), and malignant glioma (n = 2). All patients underwent biopsy or resection, followed by chemotherapy. Six patients received scheduled irradiation and six were irradiated at the time of disease progression. Ten patients are alive at a median follow-up of 11.6 years (range, 1.7-21.6 years). 5-year overall survival (OS) was 66.3% (SE 12.2%), and 5-year event-free survival (EFS) was 28.6% (SE 12.1%). Age at diagnosis was a significant predictor of the hazard of death in a Cox model (HR 2.871, 95%CI 1.015-8.123). Gender and histology did not predict OS or EFS. Trends toward improved OS were detected for patients with hemispheric tumors and those undergoing complete resection. All evaluable survivors (n = 9) had some neurocognitive impairment, with estimated overall cognitive ability ranging from significantly delayed to average; all survivors attending school (n = 5) performed below grade level on achievement testing. Seven of nine evaluable survivors had endocrine dysfunction.
Young children with high-grade astrocytoma have better long-term overall survival than older patients, but recurrence is common, and most children require irradiation. Long-term complications are frequent and often severe.
高级别星形细胞瘤在幼儿中较为罕见,但据报道其预后比老年患者的类似肿瘤更好。
我们回顾性分析了1984年至2005年间在单一机构接受治疗的3岁以下高级别星形细胞瘤患者的临床特征、生存率和长期后遗症。
共纳入16例患者。组织学类型包括间变性星形细胞瘤(n = 9)、多形性胶质母细胞瘤(n = 5)和恶性胶质瘤(n = 2)。所有患者均接受了活检或手术切除,随后进行化疗。6例患者接受了计划性放疗,6例在疾病进展时接受了放疗。10例患者在中位随访11.6年(范围1.7 - 21.6年)时仍存活。5年总生存率(OS)为66.3%(标准误12.2%),5年无事件生存率(EFS)为28.6%(标准误12.1%)。在Cox模型中,诊断时的年龄是死亡风险的显著预测因素(风险比2.871,95%置信区间1.015 - 8.123)。性别和组织学类型不能预测OS或EFS。半球肿瘤患者和接受完全切除的患者的OS有改善趋势。所有可评估的幸存者(n = 9)均有一定程度的神经认知障碍,估计总体认知能力从明显延迟到平均水平不等;所有上学的幸存者(n = 5)在学业测试中的表现均低于年级水平。9例可评估的幸存者中有7例存在内分泌功能障碍。
患有高级别星形细胞瘤的幼儿长期总体生存率比老年患者更好,但复发很常见,且大多数儿童需要放疗。长期并发症频繁且往往很严重。